Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sarah Gheuens Sells 2,909 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 2,909 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $97,567.86. Following the sale, the insider now owns 56,988 shares of the company's stock, valued at $1,911,377.52. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO traded down $0.18 during mid-day trading on Friday, reaching $33.47. The stock had a trading volume of 489,988 shares, compared to its average volume of 651,989. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of 2.98 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The business has a 50 day simple moving average of $31.27 and a 200 day simple moving average of $32.11.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank decreased their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $58.60.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at about $33,000. GF Fund Management CO. LTD. acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at about $39,000. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at about $40,000. CWM LLC lifted its position in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 996 shares during the period. Finally, Sterling Capital Management LLC lifted its position in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 1,587 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.